MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/140/0.2/19.12.25 | Real-time Bid/Ask 13:08:25 2024-07-01 EDT | ||
| 5.7 EUR / 5.72 EUR | +4.96% |
|
| Current month | +25.64% | ||
| 1 month | +28.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 5.5 | +1.10% |
| 24-06-28 | 5.44 | -1.63% |
| 24-06-27 | 5.53 | -0.18% |
| 24-06-26 | 5.54 | -5.46% |
| 24-06-25 | 5.86 | +13.13% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 09:57 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME00FU |
| ISIN | DE000ME00FU9 |
| Date issued | 2023-08-23 |
| Strike | 140 $ |
| Maturity | 2025-12-19 (536 Days) |
| Parity | 5 : 1 |
| Emission price | 1.29 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.86 € |
|---|---|
| Lowest since issue | 1.44 € |
| Spread | 0.02 € |
| Spread % | 0.35% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
